Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision)
- PMID: 26992838
- DOI: 10.1016/j.ophtha.2016.01.058
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision)
Abstract
Background: The American Academy of Ophthalmology recommendations on screening for chloroquine (CQ) and hydroxychloroquine (HCQ) retinopathy are revised in light of new information about the prevalence of toxicity, risk factors, fundus distribution, and effectiveness of screening tools.
Pattern of retinopathy: Although the locus of toxic damage is parafoveal in many eyes, Asian patients often show an extramacular pattern of damage. DOSE: We recommend a maximum daily HCQ use of ≤5.0 mg/kg real weight, which correlates better with risk than ideal weight. There are no similar demographic data for CQ, but dose comparisons in older literature suggest using ≤2.3 mg/kg real weight.
Risk of toxicity: The risk of toxicity is dependent on daily dose and duration of use. At recommended doses, the risk of toxicity up to 5 years is under 1% and up to 10 years is under 2%, but it rises to almost 20% after 20 years. However, even after 20 years, a patient without toxicity has only a 4% risk of converting in the subsequent year.
Major risk factors: High dose and long duration of use are the most significant risks. Other major factors are concomitant renal disease, or use of tamoxifen.
Screening schedule: A baseline fundus examination should be performed to rule out preexisting maculopathy. Begin annual screening after 5 years for patients on acceptable doses and without major risk factors.
Screening tests: The primary screening tests are automated visual fields plus spectral-domain optical coherence tomography (SD OCT). These should look beyond the central macula in Asian patients. The multifocal electroretinogram (mfERG) can provide objective corroboration for visual fields, and fundus autofluorescence (FAF) can show damage topographically. Modern screening should detect retinopathy before it is visible in the fundus.
Toxicity: Retinopathy is not reversible, and there is no present therapy. Recognition at an early stage (before any RPE loss) is important to prevent central visual loss. However, questionable test results should be repeated or validated with additional procedures to avoid unnecessary cessation of valuable medication.
Counseling: Patients (and prescribing physicians) should be informed about risk of toxicity, proper dose levels, and the importance of regular annual screening.
Copyright © 2016 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Comment in
-
Re: Marmor et al.: American Academy of Ophthalmology Statement: Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). (Ophthalmology 2016;123:1386-1394).Ophthalmology. 2017 Mar;124(3):e28-e29. doi: 10.1016/j.ophtha.2016.06.062. Ophthalmology. 2017. PMID: 28219513 No abstract available.
-
Reply.Ophthalmology. 2017 Mar;124(3):e29-e30. doi: 10.1016/j.ophtha.2016.06.063. Ophthalmology. 2017. PMID: 28219514 No abstract available.
Similar articles
-
Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy.Ophthalmology. 2011 Feb;118(2):415-22. doi: 10.1016/j.ophtha.2010.11.017. Ophthalmology. 2011. PMID: 21292109
-
Hydroxychloroquine and chloroquine retinopathy: a systematic review evaluating the multifocal electroretinogram as a screening test.Ophthalmology. 2015 Jun;122(6):1239-1251.e4. doi: 10.1016/j.ophtha.2015.02.011. Epub 2015 Mar 29. Ophthalmology. 2015. PMID: 25824328 Review.
-
Disparity between visual fields and optical coherence tomography in hydroxychloroquine retinopathy.Ophthalmology. 2014 Jun;121(6):1257-62. doi: 10.1016/j.ophtha.2013.12.002. Epub 2014 Jan 16. Ophthalmology. 2014. PMID: 24439759
-
Pericentral retinopathy and racial differences in hydroxychloroquine toxicity.Ophthalmology. 2015 Jan;122(1):110-6. doi: 10.1016/j.ophtha.2014.07.018. Epub 2014 Aug 31. Ophthalmology. 2015. PMID: 25182842
-
Hydroxychloroquine: A Brief Review on Screening, Toxicity, and Progression.Ophthalmic Surg Lasers Imaging Retina. 2016 Mar;47(3):207-17. doi: 10.3928/23258160-20160229-02. Ophthalmic Surg Lasers Imaging Retina. 2016. PMID: 26985794 Review. No abstract available.
Cited by
-
Decreased peri-parafoveal RPE, EZ and ELM intensity: A novel predictive biomarker for hydroxychloroquine retinal toxicity.Graefes Arch Clin Exp Ophthalmol. 2024 Jun 5. doi: 10.1007/s00417-024-06532-8. Online ahead of print. Graefes Arch Clin Exp Ophthalmol. 2024. PMID: 38836942
-
Automated Evaluation of Ellipsoid Zone At-Risk Burden for Detection of Hydroxychloroquine Retinopathy.J Pers Med. 2024 Apr 25;14(5):448. doi: 10.3390/jpm14050448. J Pers Med. 2024. PMID: 38793030 Free PMC article.
-
Microvascular Density Analysis of Patients with Inactive Systemic Lupus Erythematosus-A Two-Year Follow-Up Optical Coherence Tomography Angiography Study.J Clin Med. 2024 May 18;13(10):2979. doi: 10.3390/jcm13102979. J Clin Med. 2024. PMID: 38792521 Free PMC article.
-
Screening practices and risk assessment for maculopathy in pentosan polysulfate users across different exposure levels.Sci Rep. 2024 May 17;14(1):11270. doi: 10.1038/s41598-024-62041-y. Sci Rep. 2024. PMID: 38760453 Free PMC article.
-
Risk Factors for Hydroxychloroquine Retinopathy and Its Subtypes.JAMA Netw Open. 2024 May 1;7(5):e2410677. doi: 10.1001/jamanetworkopen.2024.10677. JAMA Netw Open. 2024. PMID: 38722628 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials